Session

Late breaking abstract: Clinical IBD highlights

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Late breaking abstract: Clinical IBD highlights  et al.

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL HEALING AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY
INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL HEALING AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY

Late breaking abstract: Clinical IBD highlights

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN’S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL
CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN’S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Late breaking abstract: Clinical IBD highlights

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS
ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Late breaking abstract: Clinical IBD highlights

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI–TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI–TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL

Late breaking abstract: Clinical IBD highlights

Item 1 - 5 / 5
1